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Huntington's disease (HD) is a neurodegenerative disease that offers an excellent paradigm for cell
replacement therapy because of the associated relatively focal cell loss in the striatum. The predominant
cells lost in this condition are striatal medium spiny neurons (MSNs). Transplantation of developing
MSNs taken from the fetal brain has provided proof of concept that donor MSNs can survive, integrate
and bring about a degree of functional recovery in both pre-clinical studies and in a limited number of
clinical trials. The scarcity of human fetal tissue, and the logistics of coordinating collection and
dissection of tissue with neurosurgical procedures makes the use of fetal tissue for this purpose both
complex and limiting. Alternative donor cell sources which are expandable in culture prior to trans-
plantation are currently being sought. Two potential donor cell sources which have received most
attention recently are embryonic stem (ES) cells and adult induced pluripotent stem (iPS) cells, both of
which can be directed to MSN-like fates, although achieving a genuine MSN fate has proven to be
difﬁcult. All potential donor sources have challenges in terms of their clinical application for regenerative
medicine, and thus it is important to continue exploring a wide variety of expandable cells. In this review
we discuss two less well-reported potential donor cell sources; embryonic germ (EG) cells and fetal
neural precursors (FNPs), both are which are fetal-derived and have some properties that could make
them useful for regenerative medicine applications.
© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Contents
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Most neurodegenerative conditions are currently untreatable
and, for the majority, treatments able to positively inﬂuence the
underlying pathogenesis are likely to be a long way off (Bartus and
Johnson, 2016; Gribkoff and Kaczmarek, 2016; Wild and Tabrizi,
2014). This makes strategies such as cell replacement therapy
attractive, because a condition may be a target for cell replacement
as long as there is relatively focal (at least in the early stages) loss of
deﬁned groups of neurons. There has been interest over the last
couple of decades in treating Huntington's disease (HD) with cell
replacement therapy. HD is a slowly progressive condition inwhich
there is relentless deterioration of cognitive, motor and psychiatric
faculties over a 20e30year period. Currently there is no available
disease-modifying treatment, but it represents a good target for cell
replacement therapy as it is a well characterised monogenetic
condition in which there is relatively focal loss of medium spiny
striatal neurons (MSN) (Rosser and Bachoud-Levi, 2012). Further-
more, it is anticipated that progress made towards achieving
functionally effective grafts in HD will be applicable to other
neurodegenerative conditions (Dunnett and Rosser, 2014).
One of the key requirements for cell replacement therapy to be
functionally effective is that the donor cells have the capacity to be
precisely differentiated into the target cell type, i.e., MSNs for HD
(Precious and Rosser, 2012). The most convincing evidence so far
that cell replacement can be effective in HD comes from both ani-
mal and human studies using donor cells derived from the whole
ganglionic eminence (WGE) in the fetal brain (Pauly et al., 2012;
Mazzocchi-Jones et al., 2009; D€obr€ossy and Dunnett, 2003). The
WGE is the area that will eventually become the adult striatum and
is where MSNs are born and develop (Deacon et al., 1994; Olsson
et al., 1995, 1998; Marin et al., 2000; Evans et al., 2012; Straccia
et al., 2016). Thus, MSNs differentiating from WGE have been
committed to an MSN lineage during the process of normal
development. Such cells are currently regarded as the “gold stan-
dard” for cell replacement in HD.
Optimal grafts result when transplants are derived from fetal
WGE collected during the peak period of MSN neurogenesis (i.e.,
approximately embryonic day 14 in rat and 8e10 weeks gestation
in human) (Dunnett and Rosser, 2011). Transplantation of devel-
oping MSNs into the degenerating striatum has been shown to
ameliorate motor and cognitive deﬁcits in animal studies, primarily
in rats and primates (Schackel et al., 2013; McLeod et al., 2013;
Paganini et al., 2014; Yhnell et al., 2016). Such studies have
allowed the mechanisms underlying the functional improvement
to be explored, and have shown that implanted cells can integrate
into the circuitry and make functional synaptic connections,
providing that they are of the appropriate phenotype (i.e., destined
to become MSNs) and were procured within the appropriate
developmental window (Dunnett and Rosser, 2014). Preliminary
evidence of functional efﬁcacy in human transplants comes from a
seminal French study that reported human fetal-derived graft
survival and signiﬁcant improvements in both motor and cognitive
function in three patients over an approximately six-year period
(Bachoud Levi et al., 2000; 2006). Enhanced FDG-positron emission
tomography signal in the frontal cortex of these individuals sug-
gested that the implanted cells had integrated into the striatal
neural circuitry and made functional connections with relevant
cortical regions (Gallina et al., 2014). The proof-of-concept provided
by this study is encouraging and demonstrates that transplantation
of “native” developing MSNs into the damaged striatum can pro-
duce functional improvements in at least some patients with HD.
Nevertheless, there is still a pressing need to undertake further
studies of fetal WGE transplantation both to conﬁrm the ability of
transplanted WGE cells to improve function and to identify thePlease cite this article in press as: Precious, S.V., et al., Is there a place
Huntington's disease?, Neurochemistry International (2017), http://dx.doparameters necessary to increase the reliability of the process and
understand which patients are most likely to beneﬁt.
For the longer term, however, it will be necessary to identify
expandable sources of donor cells for clinical application, as pri-
mary fetal cells present several challenges: they are scarce (an issue
compounded by the fact that bilateral transplants in HD require
cells from approximately four fetuses, i.e., eightWGEs); they cannot
be stored long-term (thus causing logistical problems for coordi-
nating cell collection, surgery and pathological screening of cells);
and they are difﬁcult to standardise. Thus, in addition to continuing
primary fetal transplants for the reasons outlined above, it is also
important to identify cells that can be expanded in number in vitro
and stored to facilitate GMP (Good Manufacturing Practice) pro-
duction, whilst maintaining the capability to generate striatal
MSNs.
Expandable sources of cells, including human embryonic stem
(ES) and human adult-derived induced pluripotent stem (iPS) cells,
which can be directed down neural lineages and speciﬁed to the
required cell type are reviewed extensively elsewhere (Bachoud-
Levi and Perrier, 2014; Choi et al., 2014; Ross and Akimov, 2014;
Chen et al., 2014). Here we discuss the potential of two types of
expandable cells derived from human fetal tissue; embryonic germ
(EG) cells and fetal neural precursor (FNP) cells, as potential donor
cells for cell replacement therapy in HD. The reasons for being
interested in these cell sources are ﬁrst, that human fetal tissue will
need to be collected for some time to come in order to supply cells
for proof-of-concept and optimisation studies as outlined above,
and secondly that both cell types have theoretical advantages over
hES and hiPS cells for regenerative medicine applications, as dis-
cussed further below.
2. Human embryonic germ (hEG) cells
EG cells are derived from primordial germ cells (PGCs) that
reside in the gonadal ridge of ﬁrst trimester embryos. PGCs are
induced from pluripotent epiblast cells very early in embryonic
development (Ohinata et al., 2005), and continue to express
markers of pluripotency such as Oct4, Nanog and SSEA-1 (Pashai
et al., 2012). In vivo, PGCs are unipotent and destined to give rise
exclusively to gametes, however, in vitro exposure of mouse PGCs to
exogenous ﬁbroblast growth factor (FGF) 2, leukaemia inhibitory
factor (LIF) and stem cell factor (SCF) can cause conversion to EG
cells, which proliferate rapidly and form colonies similar to those
observed when culturing ES cells (Durcova-Hills et al., 2008). EG
cells show all the hallmarks of pluripotency, including differentia-
tion into cell types from all three germ layers, as well as formation
of teratomas and chimeras (Labosky et al., 1994; Stewart et al.,
1994). So far, only a small number of laboratories have reported
successful conversion of human PGCs to human EG (hEG) cells
using FGF2, LIF and membrane-bound SCF provided through feeder
cells (Pan et al., 2005; Turnpenny et al., 2003; Shamblott et al.,
1998; Liu et al., 2004). However, most groups report that, unlike
their mouse counterparts, hEG cells do not form teratomas and
cannot be maintained in culture long-term, due to their high ten-
dency to differentiate rather than preserving pluripotent traits
(Turnpenny et al., 2006). Although resistance to pluripotency and
indeﬁnite culture presents some challenges, it also presents a
theoretical advantage in that neuronal precursors derived from
such sources may be less likely to overgrow or form tumours post-
transplantation; something that is currently a problem for many
hES cell derived donor cells (Master et al., 2007).
To explore the possibility that hEG cells could be used for cell
replacement applications, we attempted to generate our own hEG
cell cultures. Human fetal tissue was collected through the South
Wales Initiative for Transplantation (SWIFT) program in accordancefor human fetal-derived stem cells for cell replacement therapy in
i.org/10.1016/j.neuint.2017.01.016
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full ethical committee approval, and under the Cardiff University
Human Tissue Act 2004 research licence (Kelly et al., 2011). We
harvested gonadal ridges from over 100 human embryos, ranging
in age from 6 to 12 weeks gestation, and subjected them to
established methods in order to ﬁrst generate cultures of PGCs.
Harvested tissues gave rise to proliferating cells that were positive
for alkaline phosphatase (AP), regarded as a marker of pluripotency
as well as of PGCs (Fig.1A). Some also expressed SSEA-1 and SSEA-4
(Fig. 1B and C, respectively), but very few were Oct4 positive
(Fig. 1D). Over 14 days in culture the proportion of cells expressing
AP and SSEA-1 increased, with AP staining consistently more
abundant than SSEA-1 (Fig. 1E). Conversely, expression of Oct4 fell
(Fig. 1E), suggesting that AP staining, whilst convenient, is probablyFig. 1. Characterisation of the in vitro characteristics of human fetal tissue derived PGCs rev
SSEA-4 (red) but very few Oct4 (red) positive cells, D). Over 14 days in culture the propor
abundant than SSEA-1 but expression of Oct3/4 fell (E), suggesting that AP staining, whi
fragments were present in these cultures, Oct4 positive cells (red) appeared largely to be on
the culture medium used (F). Scale bar ¼ 100 mm. Abbreviations: AP e alkaline phosphatas
ﬁgure legend, the reader is referred to the web version of this article.)
Please cite this article in press as: Precious, S.V., et al., Is there a place
Huntington's disease?, Neurochemistry International (2017), http://dx.donot a reliable PGC marker on its own.
Having obtained PGCs in culture, the next step was to convert
them to stable EG cell lines. In line with the literature on hEG cell
derivation, this proved more difﬁcult. Despite using numerous
tissue samples of various ages and exploring numerous different
parameters including media components, growth factors, feeder
cells, passaging techniques and cell isolation, we failed to
convincingly generate hEG cell colonies from any of our PGC
cultures.
The manipulations tested are summarised in Table 1 and
included:
 Growth factors. All our cultures contained both FGF2 (based on
reports of successful conversion of PGCs to EG cells in bothealed: A) Alkaline phosphatase positive PGCs (dark blue/black), B) SSEA-1 (red) and C)
tion of cells expressing AP and SSEA-1 increased, with AP staining consistently more
lst convenient, is probably not a reliable PGC marker on its own. When small tissue
the outside of the fragments and formed visible clusters on the surface irrespective of
e; PGCs e primordial germ cells. (For interpretation of the references to colour in this
for human fetal-derived stem cells for cell replacement therapy in
i.org/10.1016/j.neuint.2017.01.016
Table 1
Experimental parameters applied to PGC cultures for generation of hEG-derived cell lines.
Base
mediuma
Growth factors addedb Dissociation reagentsc Feeder layer Number of
embryos
MACS
sorted
1 FGF2 (4 ng/ml),
LIF (1000U/ml)
Collagenase IV (1 mg/ml) STO 6 No
1 FGF2 (4 ng/ml),
LIF (1000U/ml)
Collagenase IV (1 mg/ml) STO; SNL; high SCF expressing clonal STO
line; 3 human gonadal somatic cell lines
7 No
2 FGF2 (2 ng/ml),
LIF (1000U/ml),
Activin A (10 ng/ml)
Trypsin/EDTA (0.25%) STO; SNL 22 Yes
1 & 2 FGF2 (4 ng/ml),
LIF (1000U/ml)
Trypsin/EDTA (0.25%) SNL 4 Yes
3 FGF2 (25 ng/ml),
Oncostatin (10 ng/ml),
SCF (10 ng/ml)
Trypsin/EDTA (0.25%) STO 9 No
3 & 2 FGF2 (2 ng/ml),
LIF (1000U/ml),
plus:
Activin A (10 ng/ml),
SCF (4 ng/ml) &
ROCK inhibitor (10 mM),
in the following combinations:
A þ R, A þ S, R þ S, A þ R þ S, Control
Trypsin/EDTA (0.25%) STO 7 No
2 FGF2 (10 ng/ml),
Oncostatin (10 ng/ml),
SCF (4 ng/ml)
Trypsin/EDTA (0.25%) JK-1; STO 8 No
4 FGF2 (10 ng/ml),
EGF (20 ng/ml),
LIF (1000U/ml),
GDNF (10 ng/ml),
SCF (100 ng/ml)
Collagenase None 16 No
4 & 2 FGF2 (10 ng/ml),
EGF (20 ng/ml),
LIF (1000U/ml),
GDNF (10 ng/ml),
SCF (100 ng/ml)
Tunica albuginea removed,
pulled into fragments in DNAse
None, or STO;
Each followed by transfer of PGC clusters
onto STO feeder layer
19 No
4 Control, FGF2 (10 ng/ml), GDNF
(10 ng/ml), SCF (100 ng/ml), plus
combinations: F þ G, S þ
F, S þ G, S þ F þ G
Tunica albuginea removed,
pulled into fragments in DNAse
None 3 No
a Base medium used: (1) k.o. DMEM (Invitrogen), 15% k.o. serum replacement (Invitrogen), 1 mM glutamine (Invitrogen), 0.1 mM non-essential amino acids (Invitrogen),
0.1 mM b-mercaptoethanol (Sigma), 100U/ml penicillin (Invitrogen), 100 mg/ml streptomycin (Invitrogen), 10 mM forskolin (Sigma) (Turnpenny et al., 2003). (2) DMEM
(Invitrogen), 15% Fetal calf serum (FCS) (Hyclone), 2 mM glutamine, 0.1 mM non-essential amino acids, 0.1 mM b-mercaptoethanol, 1 mM sodium pyruvate (Invitrogen), 100U/
ml penicillin, 100 mg/ml streptomycin, 10 mg/ml forskolin (Shamblott et al., 1998). (3) k.o. DMEM, 15% k.o. serum replacement, 1 mM glutamine, 0.1 mM non-essential amino
acids, 0.1 mM b-mercaptoethanol, 10 mM forskolin. (4) Serum-free Media (SFM) (Invitrogen), StemPro 34 supplement (Invitrogen), 1% FCS, 25 mg/ml hr-insulin (Sigma), 200 mg/
ml hr-transferrin (Sigma), 60 mM putrescine (Sigma), 30 nM sodium selenite (Sigma), 6 mg/ml D-glucose (Sigma), 30 mg/ml pyruvic acid, 1 ml/ml DL-lactic acid (Sigma), 5 mg/ml
BSA (Sigma), 2 mM L-glutamine, 0.1mM b-mercaptoethanol, 1%minimal essential medium vitamin solution (Invitrogen), 0.1 M ascorbic acid (Sigma), 10 mg/ml d-Biotin (Sigma),
30 ng/ml b-estradiol (Sigma), 60 ng/ml progesterone (Sigma), 10 mg/ml forskolin (Kanatsu-Shinohara et al., 2003). NB: unless indicated, penicillin and streptomycin were not
added to culture medium as they may interfere with maintenance of some stem cell populations.
b Growth factors were obtained from: FGF2 (R&D Systems), LIF (Sigma), Oncostatin, EGF (Sigma), SCF (Sigma), GDNF (Peprotech), Activin A (Peprotech). Control is deﬁned as
base medium only with no growth factors added.
c Dissociation reagents were obtained from: Collagenase IV (Invitrogen), Trypsin EDTA (Invitrogen), ROCK inhibitor (Merck Chemicals), DNAse (Sigma). Feeder layers used are
deﬁned as: STO (mouse embryonic ﬁbroblast line (ATCC CRL-1503); SNL is a LIF-expressing clonal STO cell line; JK-1 is a spontaneously immortalised testicular stromal cell
line.
S.V. Precious et al. / Neurochemistry International xxx (2017) 1e84mouse and human (Shamblott et al., 1998; Turnpenny and
Hanley, 2007)) and either LIF or oncostatin, another member
of the interleukin-6 family that has overlapping activity (Mosley
et al., 1996). We also tested: soluble SCF, required for survival
and proliferation of PGCs (Tu et al., 2007; Dolci et al., 1991;
Godin et al., 1991; Matsui et al., 1991); GDNF, found in female
germ cells and needed for germ cell survival in male mice (Miles
et al., 2012; Farhi et al., 2010); EGF, which induces proliferation
in chick PGCs (Ge et al., 2009); and the nodal signallingmolecule
activin A, which is critical for maintenance of pluripotency in
human cells and stimulates Oct4 transcription in spermatogo-
nial stem cells (Vallier et al., 2005; He et al., 2009). None of these
factors, either alone or in combination, led to the appearance of
pluripotent hEG cells.
 High dose (100 ng/ml) SCF supplementation, added to either
StemPro 34 medium or standard medium containing 15% fetalPlease cite this article in press as: Precious, S.V., et al., Is there a place
Huntington's disease?, Neurochemistry International (2017), http://dx.docalf serum (FCS), as this has been reported to promote colony
formation of germ cells in mixed fetal gonadal cultures grown
without feeder cells (Tu et al., 2007). We observed that when
small tissue fragments were present in these cultures, Oct4
positive cells appeared on the outside of the fragments and
formed visible clusters on the surface, irrespective of the culture
medium used (Fig. 1F). With continued culture, the somatic cells
of the gonadal fragments also attached to the dish and spread
out to form a monolayer on which PGCs migrated out. Twenty-
four hours after plating, PGC clusters could be removed under a
dissection microscope and transferred to feeder-coated plates,
where they remained visible for several weeks but did not
convert into hEG cell colonies.
 Various feeder layers. The STOmouse embryonic ﬁbroblasts cell
line (ATCC CRL-1503) has been reported as the most successful
cell line for this purpose (Turnpenny and Hanley, 2007;for human fetal-derived stem cells for cell replacement therapy in
i.org/10.1016/j.neuint.2017.01.016
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that sub-clones can vary considerably in their properties,
including expression of membrane bound SCF. We used several
cloned STO lines, the spontaneously immortalised testicular
stromal cell line JK-1 (Kim et al., 2008), and several non-
transformed lines of human fetal somatic ﬁbroblast-like cells
(He et al., 2007).
 PGC puriﬁcation. A practical obstacle to maintaining cultures of
PGCs was the high proliferative capacity of somatic gonadal
cells. We attempted magnetic bead puriﬁcation (MACS) using
the pluripotency marker CD133, which is expressed in the
germline (Gashaw et al., 2007). However, this did not result in a
sufﬁciently pure population of human PGCs that avoided
contaminationwith somatic cells. As germ cells are highly prone
to apoptosis in vitro, preventing isolation by FACS, we attempted
a gentler approach by adapting methods developed for isolating
spermatogonial stem cells from adult testis samples using a
three-step matrix selection process on plastic, collagen and
laminin, followed by culturing on feeder cells to induce con-
version to pluripotent stem cells (Conrad et al., 2008). However,
PGCs did not form clusters under these conditions.
Despite the numerous different manipulations carried out in a
large number of fetal samples, and the successful (albeit short-
term) culture of PGCs, we were unable to generate any hEG cell
lines.We did, however, observe an effect of high SCF concentrations
on human PGC adhesion and migration, which could lead to future
tools for isolating this highly vulnerable cell type. It seems likely
that the factors which can induce de-differentiation of mouse PGCs
to a pluripotent state are not sufﬁcient for the human equivalent.
This is congruent with the fact that no long-term expandable hEG
cell lines have become available to researchers, despite their gen-
eration ﬁrst being reported in 1998 (Shamblott et al., 1998).
Fundamental differences between mouse and human gamete for-
mation may further prevent establishment of stable hEG cell lines,
the timing and regulation of epigenetic re-programming being
obvious candidates.
3. Fetal-derived neural precursors (FNPs)
It has long been known that proliferative cells with the capacity
to differentiate into cells of a neural lineage (FNPs) can be isolated
from the developing fetal WGE, and other brain regions. This was
initially shown in rodents (Reynolds et al., 1992) and since then
numerous papers have demonstrated similar ﬁndings in both ro-
dent and human (Murphy et al., 1990, 1994; Bartlett et al., 1995;
Fricker et al., 1995). There are clear species differences in the re-
sponses of FNPs to speciﬁc proliferation media, with murine cells
tending to proliferate for much longer periods of time than rat and
porcine cells (Svendsen et al., 1998; Ciccolini and Svendsen, 1998;
Armstrong et al., 2000, 2002). In addition, if hFNPs could survive
cryopreservation this would ease current practical constraints
associated with scheduling the neurosurgery and would also
permit at least some standardisation of the cells, which cannot
currently be achieved for primary hWGE. Speciﬁcally, hWGE can
only be reliably held in culture (using media to reduce metabolic
processes, ie “hibernation”) for a short period of time (up to 8 days;
Hurelbrink et al., 2000). This is not a long enough period of time to
permit full quality control of the tissue. Furthermore, FNPs are
multipotent, rather than pluripotent, and are lineage restricted.
Thus they are less likely to give rise to fast-growing tumours
following grafting, in contrast to grafts of pluripotent-derived cells.
A major problem for use of FNPs for regenerative medicine has
been the tendency for hFNPs to produce progressively fewer neu-
rons with increasing periods of time in culture. Furthermore,Please cite this article in press as: Precious, S.V., et al., Is there a place
Huntington's disease?, Neurochemistry International (2017), http://dx.dohWGE-derived FNPs that have undergone passaging in vitro pro-
duce fewer MSN-like neurons and survive poorly following trans-
plantation into rodent HD models (Caldwell et al., 2001; Zietlow
et al., 2012). We have previously suggested that the loss of neuro-
genic potential may be due to loss of positional information as the
hFNPs continue to proliferate in the absence of developmental
signals to which they would normally have been exposed during
development in the embryo (Zietlow et al., 2005). Indeed, PCR
analysis of mouse WGE-derived FNPs, compared to primary WGE,
shows a dramatic fall in the levels of striatal-speciﬁc gene expres-
sion (unpublished observations), although in human cells, at least
over the ﬁrst few passages, the expression of striatal markers
appeared relatively stable (Martín-Iba~nez et al., 2016). Despite this
apparent phenotypic change, short term proliferation of hFNPs still
results in a modest increase in cell number (1.6 fold increase in cell
number over 10 days in culture), which could have important
practical applications (Kelly et al., 2007).
Previous data of ours suggests that, in contrast to transplanted
long-term expanded hFNPs, transplants of short-term (10 day)
expanded WGE-derived hFNPs retain the ability to survive and
integrate into the host brain (Kelly et al., 2007). This study reported
that grafts of 10 day expanded hFNPs analysed after 12 weeks
survival in vivo sent out ﬁbre projections that were target-speciﬁc
for cells of that origin. Furthermore, the hFNP grafts produced
more profuse outgrowths than did primary WGE grafts (Kelly et al.,
2007). This data was encouraging in that it suggested that short-
term expanded FNPs had a potential to reconnect neural circuitry
that is as good, if not better, than that of primary fetal cells, but their
low proliferative potential made them less attractive than the
highly proliferative pluripotent stem cells. However, recent reports
have highlighted that the challenge of directing hES cells to a
genuine MSN phenotype capable of ameliorating functional deﬁcits
has so far been greater than initially anticipated. There are sporadic
reports of limited improvements in small preclinical studies, for
example some improvement in rotation following ES cell-derived
MSN grafts (Delli Carri et al., 2013), but to date this falls consider-
ably short of the sorts of improvements seen in rat allografts and
the more successful human allograft studies. Thus, we suggest that
it is important to continue exploring alternative donor cell sources
and recently we have begun again to consider the potential of
short-term expanded hFNPs as donor cells for regenerative medi-
cine. These cells may have the capacity to more readily respond to
developmental signals that would allow them to maintain their
identity over the period of expansion in culture. Such ‘epigenetic
memory’ has been suggested from work in several adult somatic
tissues (Hiler et al., 2015) and may be an important aspect of these
cells and allow a more adaptable approach for generating large
populations of MSNs for clinical application.
In a comparison of hFNP and hWGE grafts 20 weeks post-
transplantation, graft-derived DARPP32 positive cells (a classic
marker of MSNs) were seen both in primary WGE and expanded
WGE grafts (Fig. 2), and stereological analysis revealed no signiﬁ-
cant difference in the number of graft-related DARPP-32- positive
neurons (Fig. 2A). Both primary and expanded FNP grafts were also
positive for calbindin (stains both MSN and striatal interneurons).
Interestingly, hFNP grafts differed from hWGE grafts in an impor-
tant aspects of morphological structure; WGE grafts are typically
organised into “P zones” (containing mostly striatal-like cells),
which stain for a variety of markers, including acetylcholinesterase
(AChE), and “non P zones” containing mostly non-striatal (probably
cortical-like) cells (Graybiel et al., 1989; Wictorin, 1992). The hFNP
grafts appeared to show very weak, or no organisation into such
zones, as shown by AChE staining (Fig. 2B). Our own interpretation
of this is that the hFNP grafts may present an advantage in their lack
of non-P zones; non-P zones are thought to result from corticalfor human fetal-derived stem cells for cell replacement therapy in
i.org/10.1016/j.neuint.2017.01.016
Fig. 2. Primary versus 10 day expanded WGE cells. A) Graph showing DARPP-32 counts in vivo. There was no signiﬁcant difference between the number of DARPP-32/HuNu
positive cells within the graft area in primary and 10 day expanded grafts. B) Photomicrograph of Primary and expanded FNP AChE stained sections. AChE is used as a
marker of striatal-like “P zones” (arrows in A). Primary WGE grafts show organisation in to P and non-P zones, as expected, in contrast to expanded FNP graft which have fewer P
zones and display a more homogeneous structure. C) Photomicrographs of sections from Primary and 10 day expanded hFNPs transplanted to the rodent lesioned striatum.
Primary grafts contained DARPP-32/HuNu positive cells (A) and (C; higher power of A), as well as calbindin/HuNu positive cells (B) and arrow in (D; higher power of B). Expanded
hFNP grafts also contained DARPP-32/HuNu positive cells (E) and (G; higher power of E), and Calbindin/HuNu positive cells (F) and (H; higher power of F) (arrows in H). Not all
calbindin cells within the graft area were HuNu positive (asterisk in H). Scale bar ¼ 100 mm. Abbreviations: AChE e acetylcholinesterase; HuNu e human nuclear antigen.
S.V. Precious et al. / Neurochemistry International xxx (2017) 1e86progenitors which migrate through the WGE during development
and thusmay ‘dilute’ the effect of the graft. However, it is important
to emphasise that this is speculation and further studies are needed
to resolve this issue.
To date, there is very limited literature reporting on functional
assessments of hFNP grafts in HD models. McBride et al in 2004
reported improved functional effect on the cylinder task following
transplantation of human cortical derived FNPs in the quinolinic
acid lesion model of HD (McBride et al., 2004). However, this was
not supported by histological evidence of graft-derived MSNs,
based on DARPP-32 expression 8 weeks post transplantation. This
relatively short time course for graft maturation may be the reasonPlease cite this article in press as: Precious, S.V., et al., Is there a place
Huntington's disease?, Neurochemistry International (2017), http://dx.dofor the lack of DARPP-32 expression along with the fact that the
cells were derived from the developing cortex, rather than WGE,
andwere expanded in culture for a long period of time, which as we
have shown previously is not supportive to good graft survival
(Zietlow et al., 2005, 2012). Studies using human fetal tissue-
derived neural precursor immortalised cell lines have also re-
ported survival, differentiation and integration of transplanted cells
with modest behavioural recovery in some cases (for example
Roberts et al., 2006; Ryu et al., 2004). However, it is clear that
systematic studies examining the functional effects of WGE-
derived FNPs in HD models are required.
In summary, there is some evidence that hFNPs retain the abilityfor human fetal-derived stem cells for cell replacement therapy in
i.org/10.1016/j.neuint.2017.01.016
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in vitro, and also that they are capable of projecting to target speciﬁc
brain regions. It is important to acknowledge that most studies to
date, including the ones presented here, have relied on default
neuronal differentiation of the transplanted FNPs post-
transplantation. That is, FNPs are precursor cells, and in these ex-
periments they have not undergone directed differentiation to-
wards speciﬁc neuronal phenotypes. An important next step will be
to subject FNPs to molecules known to be important for MSN
differentiation.
4. Concluding remarks
In conclusion, we review the potential of two major sources of
fetal-derived stem cells as donor cells for regenerative medicine in
HD. At this stage in the development of CNS regenerative medicine
it is important to properly consider all possible donor cell sources,
as there are factors associated with each that make them more or
less suitable for individual conditions. For example, another strat-
egy is the use of fetal-derived iPSCs, on the basis that they may
possess a different range of properties to adult-derived iPSCs, but
there is currently very little literature in this area. Here we discuss
our extensive attempts to produce hEG cells, which wewere unable
to convincingly generate and maintain, and this is consistent with
the small numbers of reports of successful conversion in the liter-
ature. Further exploration of this cell type will need to await a
better understanding of the biology of hPGCs. In contrast, we
suggest that FNPs hold more promise. Although they cannot as yet
be regarded as potential donor cells for neural transplantation, we
suggest that there is sufﬁcient positive data to support further
exploration of their potential.
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